BCB Bancorp shares dip after insider purchase, CEO prepares for credit review

BCB Bancorp shares dip after insider purchase, CEO prepares for credit review

June 5, 2026

New York, June 5, 2026, 16:03 EDT

BCB Bancorp shares slipped Friday, giving up some gains from earlier this week’s run of leadership buying. A filing showed director Gerald Werdann picked up almost $50,000 in stock as investors looked for new Chief Executive Thomas M. O’Brien to lay out how he’ll handle credit issues.

BCBP ended regular Nasdaq trading at $11.25, down 0.75%. Volume for the New Jersey community bank hit 184,642 shares, with the stock moving between $11.20 and $11.57 during the day.

Form 4 filings out late showed Werdann picking up 4,400 shares at $11.28 each on June 4 via the BGJ Family Trust, bringing the trust’s stake up to 12,122 shares. Small buy, but it ticked up reported insider holdings. ([SEC][2])

BCB named O’Brien as its new president and CEO on Monday, pushing a leadership shake-up that the board says is aimed at fixing “recent operational and credit challenges.” Chairman Mark D. Hogan said in a statement the move was necessary. O’Brien told investors he is looking to lay out “meaningful clarity” on strategy by late summer. GlobeNewswire

O’Brien’s initial remarks zeroed in on credit, capital and valuation. In an SEC transcript, he said he’ll need about 90 days to get fully briefed. He also flagged “criticized and classified loans”—those judged weaker or riskier—as a key area to size up quickly. SEC

O’Brien didn’t mince words on what matters now. “Job 1 through 10” is credit clarity in coming quarters, he told investors. He also said the bank should stay “comfortably well capitalized.” Raising capital means selling new securities to shore up the balance sheet. That can help, but if the price is low, it risks diluting current shareholders.

Company moves were in focus late. OceanFirst Financial picked up 2.1%. ConnectOne Bancorp edged up 0.4%. Provident Financial Services added 0.8%. BCBP slipped even though a director bought shares.

Banks traded in a mixed environment. U.S. stocks slid across the board as jobs data beat forecasts, bringing worries the Federal Reserve may keep policy tighter for longer. Peter Cardillo, chief market economist at Spartan Capital Securities, told Reuters the report gave “another reason” to expect the Fed’s next move could be a rate hike. Higher rates tend to lift loan yields, but also keep deposit and funding costs up. Reuters

BCB swung back to a profit in the first quarter after struggling to end 2025. Net income was $4.9 million, or 26 cents a share. Non-accrual loans dropped to $59.8 million as of March 31, down from $63.3 million at December’s close.

The earnings release showed there’s more to do. Net loans dropped. The allowance for credit losses was 54.5% of non-accrual loans. Net charge-offs totaled $3.9 million in the quarter, including loans written off after recoveries.

O’Brien is focusing less on growing loans right now and more on tangible book value, which strips out things like goodwill to show a bank’s net worth. For small banks, that’s important. Investors often look at book value to see if bad loans have already taken a hit.

The risk is the review could reveal larger losses, mean a capital raise, or leave the stock trading below book value for longer. In its filing, the company pointed to higher inflation, the economy, liquidity and capital issues, deposit flows, credit quality and real estate values as factors that could make actual results different from what management expects.

The story so far: a small insider purchase, a new CEO known for handling tough banks, and a loose deadline late this summer or the third-quarter report. Investors want to see something more concrete by then than just general plans to fix things.

[2]: https://www.sec.gov/Archives/edgar/data/0001228454/000119312526258512/xslF345X06/ownership.xml “SEC FORM
4″

Stock Market Today

  • Investors React to CSL's US$5 Billion Vifor Impairment and Guidance Update
    June 5, 2026, 4:11 PM EDT. CSL Limited announced a US$5 billion non-cash impairment primarily linked to its Vifor unit, alongside a cut in FY26 revenue guidance to around US$15.2 billion. The impairment and guidance reset reflect previous capital allocation challenges and ongoing operational restructuring aimed at enhancing the company's plasma, vaccines, and iron therapy businesses. CSL targets US$500-550 million in annual cost savings by FY28 to support margins. Investor sentiment is cautious, with some analysts revising down growth forecasts and earnings projections for 2029. The company projects revenue of US$17.2 billion and earnings of US$3.3 billion by 2029, suggesting a potential 49% upside to current share price. The developments underline risks and credibility concerns amid a broad transformation effort.